Knight Therapeutics Announces Receipts for Final Prospectuses and Conditional Approval for Listing on the Toronto Stock Exchange

MONTREAL, CANADA--(Marketwired - April 17, 2014) -

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Knight Therapeutics Inc. ("Knight" or the "Company") (TSX VENTURE:GUD) today announced that it has received receipts dated April 17, 2014 for its short form prospectuses both dated April 17, 2014 (the "Final Prospectuses") filed with the securities regulatory authorities in the applicable provinces of Canada with respect to the distribution of an aggregate of 55,728,580 Common Shares (as defined below) issuable pursuant to the exercise of an aggregate of 55,728,580 common share special warrants (the "Special Warrants"). 21,428,580 Special Warrants were issued on March 19, 2014 at a price of $3.50 per Special Warrant pursuant to an underwritten private placement through a syndicate of underwriters led by GMP Securities L.P. ("GMP") and including Cormark Securities Inc. ("Cormark") and 34,300,000 Special Warrants were issued on April 10, 2014 at a price of $5.25 per Special Warrant pursuant to an underwritten private placement through a syndicate of underwriters co-led by GMP and Cormark, and including Bloom Burton & Co. as a selling group member. In accordance with the indentures governing the Special Warrants, each Special Warrant entitles the holder thereof to receive one Common Share on the exercise or deemed exercise of the Special Warrant for no additional consideration. All unexercised Special Warrants will be deemed to have been exercised without the payment of additional consideration or further action on the part of the holder within five (5) business days from the date hereof.

Following the date of the deemed exercise of the Special Warrants, Knight will have an aggregate of 77,764,640 common shares ("Common Shares") issued and outstanding. "Knight now has approximately $250 million of cash, an FDA priority review voucher which we intend to sell, and royalties associated with the sale of Impavido. Including the U.S. FDA approval last month, Impavido is approved for the treatment of leishmaniasis in 16 countries. In short, we have all the necessary tools to start building," said Jonathan Ross Goodman, President & CEO of Knight Therapeutics Inc.